Benefits
Craving control and emotional eating management
Supresa® addresses the reward-driven component of eating that drives overconsumption beyond physical hunger — the desire for specific foods (sweet, salty, fatty) driven by dopaminergic reward circuits and serotonergic mood pathways. By modulating these neurobiological craving drivers, Supresa® helps consumers manage the most challenging aspect of caloric control: wanting to eat when not hungry.
Stress-induced snacking reduction
Chronic stress elevates cortisol, which drives cravings for high-calorie comfort foods and impairs the prefrontal cortex's ability to override impulse eating. Supresa® targets the stress-eating connection through adaptogenic and serotonergic mechanisms that reduce cortisol-driven food-seeking behavior and improve emotional regulation around food choices.
Weight management support through behavioral food control
Rather than suppressing physical hunger through appetite-hormone manipulation alone, Supresa® provides a more sustainable weight management pathway by improving the behavioral control over eating — reducing impulsive and reward-driven caloric consumption that drives weight gain in most people beyond simple caloric miscalculation.
Mechanism of action
Serotonergic and dopaminergic craving pathway modulation
Supresa® botanical actives modulate serotonin (5-HT2C receptor agonism or serotonin reuptake inhibition) and dopamine reward signaling in the mesolimbic system — reducing the hedonic drive to consume high-reward foods without physical hunger. Serotonergic modulation also addresses the mood component of emotional eating by improving mood stability and stress resilience that drive compensatory eating behaviors.
Clinical trials
Clinical study examining Supresa® effects on food cravings, snacking behavior, and weight management outcomes.
Adult Indian men and women. Randomized, double-blind, placebo-controlled trial of Caralluma fimbriata extract (a key component of Supresa®) on appetite, food intake, and anthropometry over 60 days.
C. fimbriata significantly reduced waist circumference and showed trends toward reduced hunger ratings vs placebo. Foundational RCT for Caralluma's appetite-suppressant claims via hypothalamic NPY downregulation and ghrelin modulation. Note: this trial used Caralluma alone, not the full Supresa® Ziziphus + Caralluma blend; the specific Supresa® branded RCT has not been published in PubMed-indexed journals. A 2021 systematic review (PMID 34758791) found mixed results across 7 trials. Component evidence supports appetite-control mechanism.